Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efalizumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Efalizumab | DRUG | - |
Inclusion Criteria: 1. Signed informed consent 2. Plaque psoriasis covering ³10% of total BSA 3. Diagnosis of plaque psoriasis for at least 6 months 4. A minimum PASI score of 12.0 at screening 5. In the opinion of the investigator, candidate for systemic therapy for psoriasis 6. Body weight of £12...
Efalizumab is being developed for the treatment of moderate to severe psoriasis, a chronic inflammatory skin condition. It is a monoclonal antibody studied in adult patients aged 18 years and older. Development is at the Phase 3 stage, and the drug is investigational rather than approved.
Efalizumab targets ITGAL and ITGB2, also known as the alpha and beta subunits of lymphocyte function associated antigen 1 (LFA-1). It acts as an inhibitor of these targets. By binding LFA-1, the antibody is designed to interfere with the molecular interactions involved in T cell activation and trafficking.
Efalizumab is being developed by Merck KGaA, which trades under the ticker MKGAF. The company is the sponsor associated with the clinical development program for the drug in moderate to severe psoriasis.
Efalizumab is in Phase 3 clinical development for moderate to severe psoriasis. It is an investigational monoclonal antibody and has not been established as an approved therapy based on the development information available. The program includes one completed Phase 3 trial.
Efalizumab has been studied in the Phase 3 trial NCT00442650, titled Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis. That trial is completed and was conducted in Switzerland with adults aged 18 years and older. It was an uncontrolled study, and no active trials are currently listed.
Efalizumab is also known by the brand name Raptiva. Both names refer to the same monoclonal antibody developed by Merck KGaA for moderate to severe psoriasis, so searches for either name point to the same drug asset and the same clinical development program.